Cargando…

Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus

The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Yufeng, Liu, Tao, Li, Jingfeng, Kaweme, Natasha Mupeta, Wang, Xinghuan, Zhou, Fuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082543/
https://www.ncbi.nlm.nih.gov/pubmed/33936026
http://dx.doi.org/10.3389/fimmu.2021.580147
_version_ 1783685861499469824
author Shang, Yufeng
Liu, Tao
Li, Jingfeng
Kaweme, Natasha Mupeta
Wang, Xinghuan
Zhou, Fuling
author_facet Shang, Yufeng
Liu, Tao
Li, Jingfeng
Kaweme, Natasha Mupeta
Wang, Xinghuan
Zhou, Fuling
author_sort Shang, Yufeng
collection PubMed
description The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influencing the IgG antibodies’ seroconversion. A total of 1,111 patients with mild to moderate COVID-19 symptoms admitted to Leishenshan Hospital in Wuhan were retrospectively analyzed. A serologic SARS-CoV-2 IgM/IgG antibody test was performed on all the patients 21 days after the onset of symptoms. Patient clinical characteristics were compared. In the study, 42 patients progressed to critical illness, with 6 mortalities reported while 1,069 patients reported mild to moderate disease. Advanced age (P = 0.028), gasping (P < 0.001), dyspnea (P = 0.024), and IgG negativity (P = 0.006) were associated with progression to critical illness. The mortality rate in critically ill patients with IgG antibody was 6.45% (95% CI 1.12–22.84%) and 36.36% (95% CI 12.36–68.38%) in patients with no IgG antibody (P = 0.003). Symptomatic patients were more likely to develop IgG antibody responses than asymptomatic patients. Using univariable analysis, fever (P < 0.001), gasping (P = 0.048), cancer (P < 0.001), cephalosporin (P = 0.015), and chloroquine/hydroxychloroquine (P = 0.021) were associated with IgG response. In the multivariable analysis, fever, cancer, cephalosporins, and chloroquine/hydroxychloroquine correlated independently with IgG response. We determined that the absence of SARS-CoV-2 antibody IgG in the convalescent stage had a specific predictive role in critical illness progression. Importantly, risk factors affecting seropositivity were identified, and the effect of antimalarial drugs on antibody response was determined.
format Online
Article
Text
id pubmed-8082543
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80825432021-04-30 Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus Shang, Yufeng Liu, Tao Li, Jingfeng Kaweme, Natasha Mupeta Wang, Xinghuan Zhou, Fuling Front Immunol Immunology The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influencing the IgG antibodies’ seroconversion. A total of 1,111 patients with mild to moderate COVID-19 symptoms admitted to Leishenshan Hospital in Wuhan were retrospectively analyzed. A serologic SARS-CoV-2 IgM/IgG antibody test was performed on all the patients 21 days after the onset of symptoms. Patient clinical characteristics were compared. In the study, 42 patients progressed to critical illness, with 6 mortalities reported while 1,069 patients reported mild to moderate disease. Advanced age (P = 0.028), gasping (P < 0.001), dyspnea (P = 0.024), and IgG negativity (P = 0.006) were associated with progression to critical illness. The mortality rate in critically ill patients with IgG antibody was 6.45% (95% CI 1.12–22.84%) and 36.36% (95% CI 12.36–68.38%) in patients with no IgG antibody (P = 0.003). Symptomatic patients were more likely to develop IgG antibody responses than asymptomatic patients. Using univariable analysis, fever (P < 0.001), gasping (P = 0.048), cancer (P < 0.001), cephalosporin (P = 0.015), and chloroquine/hydroxychloroquine (P = 0.021) were associated with IgG response. In the multivariable analysis, fever, cancer, cephalosporins, and chloroquine/hydroxychloroquine correlated independently with IgG response. We determined that the absence of SARS-CoV-2 antibody IgG in the convalescent stage had a specific predictive role in critical illness progression. Importantly, risk factors affecting seropositivity were identified, and the effect of antimalarial drugs on antibody response was determined. Frontiers Media S.A. 2021-04-15 /pmc/articles/PMC8082543/ /pubmed/33936026 http://dx.doi.org/10.3389/fimmu.2021.580147 Text en Copyright © 2021 Shang, Liu, Li, Kaweme, Wang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shang, Yufeng
Liu, Tao
Li, Jingfeng
Kaweme, Natasha Mupeta
Wang, Xinghuan
Zhou, Fuling
Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title_full Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title_fullStr Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title_full_unstemmed Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title_short Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
title_sort impact of treatment regimens on antibody response to the sars-cov-2 coronavirus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082543/
https://www.ncbi.nlm.nih.gov/pubmed/33936026
http://dx.doi.org/10.3389/fimmu.2021.580147
work_keys_str_mv AT shangyufeng impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus
AT liutao impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus
AT lijingfeng impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus
AT kawemenatashamupeta impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus
AT wangxinghuan impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus
AT zhoufuling impactoftreatmentregimensonantibodyresponsetothesarscov2coronavirus